Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration
Top Cited Papers
- 10 June 2016
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 48 (3), 632-647
- https://doi.org/10.1183/13993003.01888-2015
Abstract
Bronchiectasis is a disease of renewed interest in light of an increase in prevalence and increasing burden on international healthcare systems. There are no licensed therapies, and large gaps in knowledge in terms of epidemiology, pathophysiology and therapy. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) is a European Respiratory Society (ERS) Clinical Research Collaboration, funded by ERS to promote high-quality research in bronchiectasis. The objective of this consensus statement was to define research priorities in bronchiectasis. From 2014 to 2015, EMBARC used a modified Delphi process among European bronchiectasis experts to reach a consensus on 55 key research priorities in this field. During the same period, the European Lung Foundation collected 711 questionnaires from adult patients with bronchiectasis and their carers from 22 European countries reporting important research priorities from their perspective. This consensus statement reports recommendations for bronchiectasis research after integrating both physicians and patients priorities, as well as those uniquely identified by the two groups. Priorities identified in this consensus statement provide the clearest possible roadmap towards improving our understanding of the disease and the quality of care for patients with bronchiectasis.Keywords
This publication has 72 references indexed in Scilit:
- Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and TrendsPLOS ONE, 2013
- Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised studyEuropean Respiratory Journal, 2012
- The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of ExacerbationsPLOS ONE, 2012
- Transmissible strains ofPseudomonas aeruginosain cystic fibrosis lung infectionsEuropean Respiratory Journal, 2012
- Significance of the microbiome in obstructive lung diseaseThorax, 2012
- Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infectionJCI Insight, 2011
- Effects of pulmonary rehabilitation in bronchiectasis: A retrospective studyChronic Respiratory Disease, 2011
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- Fluctuations in phenotypes and genotypes within populations of Pseudomonasaeruginosa in the cystic fibrosis lung during pulmonary exacerbationsJournal of Medical Microbiology, 2010
- Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factorsThorax, 2002